KMYY(SH:600518) Zheng Quan Zhi Xing·2025-08-29 08:25Core Viewpoint - Kangmei Pharmaceutical Co., Ltd. reported a revenue increase of 4.17% year-on-year for the first half of 2025, indicating a positive trend in its financial performance despite a slight decline in total assets [1][2]. Financial Summary - Total assets at the end of the reporting period were approximately CNY 13.64 billion, a decrease of 1.11% compared to the end of the previous year [1]. - The net assets attributable to shareholders of the listed company were approximately CNY 7.19 billion, showing a slight increase of 0.23% year-on-year [1]. - Operating revenue for the reporting period was approximately CNY 2.58 billion, up from CNY 2.47 billion in the same period last year [1]. - Total profit for the period was approximately CNY 28.52 million, representing a year-on-year increase of 14.93% [1]. - Net profit attributable to shareholders of the listed company was approximately CNY 16.90 million, an increase of 7.24% compared to the previous year [1]. - The net profit from regular operations was reported as a loss of approximately CNY 3.62 million, an improvement from a loss of CNY 108.13 million in the same period last year [1]. - The net cash flow from operating activities was a negative CNY 82.12 million, an improvement from a negative CNY 318.86 million in the previous year [1]. - The weighted average return on net assets was 0.24%, an increase from 0.22% in the previous year [1]. - Basic and diluted earnings per share were both CNY 0.001, unchanged from the previous year [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 305,336 [1]. - The largest shareholder, Guangdong Shennongshi Enterprise Management Partnership, held 25.31% of the shares, amounting to approximately 3.51 billion shares [2].